Heat-treated fungizone retains amphotericin B antifungal activity without renal toxicity in rats infected with Aspergillus fumigatus

Pharmaceutical Research

Volumn 21, Issue 9, 2004, Pages 1564-1566

  Sivak, Olena ^a   Bartlett, Karen ^a   Wasan, Kishor M ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Antifungal activity; Aspergillus fumigatus; Fungizone; Heat treated amphotericin B; Rats

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B DEOXYCHOLATE; ANTIBIOTIC AGENT; ANTIFUNGAL AGENT;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIFUNGAL ACTIVITY; ARTICLE; ASPERGILLOSIS; ASPERGILLUS FUMIGATUS; COLONY FORMING UNIT; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG EFFICACY; FUNGAL VIRULENCE; HEAT TREATMENT; LIVER TOXICITY; MALE; NEPHROTOXICITY; NONHUMAN; PRIORITY JOURNAL; RAT; ANIMAL; CHEMICALLY INDUCED DISORDER; CHEMISTRY; DRUG SCREENING; DRUG STABILITY; EVALUATION; HEAT; KIDNEY DISEASE; SPRAGUE DAWLEY RAT;

AMPHOTERICIN B; ANIMALS; ANTIFUNGAL AGENTS; ASPERGILLOSIS; ASPERGILLUS FUMIGATUS; DRUG EVALUATION, PRECLINICAL; DRUG STABILITY; HEAT; KIDNEY DISEASES; MALE; RATS; RATS, SPRAGUE-DAWLEY;

EID: 20444446829     PISSN: 07248741     EISSN: None     Source Type: Journal    
DOI: 10.1023/B:PHAM.0000041449.46054.b4     Document Type: Article

References (22)

1. E. Roilides, C. A. Layman, J. Filioti, O. Akpogheneta, T. Sein, C. G. Lamaignere, R. Petraitiene, and T. J. Walsli. Amphotericin B formulations exert additive antifungal activity in combination with pulmonary alveolar macrophages and polymorphonuclear leukocytes against Aspergillus fumigatus. Antimicrob. Agents Chemother. 46:1974-1976 (2002).
2. G. P. Bodey. Infection in cancer patients: A continuing association. Am. J. Med. 81:11-26 (1986).
3. G. G. Chabot, R. Pazdur, F. A. Valeriote, and L. H. H. Baker. Pharmacokinetics and toxicity of continuous infusion of amphotericin B in cancer patients. J. Pharm. Sci. 78:307-310 (1989).
4. P. Chavanet, V. Joly, D. Rigaud, J. Bolard, C. Carbon, and P. Yenni. Influence of diet on experimental toxicity of amphotericin B deoxycholate. Antimicrob. Agents Chemother. 38:963-968 (1994).
5. M. E. Klesper, E. J. Wolfe, and M. A. Pfaller. Antifungal pharmacodynamic characteristics of fluconazole and amphotericin B against Cryptococcus neoformans. J. Antimicrob. Chemother. 41: 397-401 (1998).
6. R. D. Meyer. Current role of therapy with amphotericin B. Clin. Infect. Dis. 14:S154-S160 (1992).
7. D. A. Rothon, R. G. Mathias, and M. T. Schechter. Prevalence of HIV infection in provincial prisons in British Columbia. Can. J. Med. Assoc. 151:S154-S160 (1994).
8. K. M. Wasan and J. S. Conklin. Enhanced Amphotericin B nephrotoxicity in intensive care patients with elevated levels of low-density lipoprotein cholesterol. Clin. Infect. Dis. 24:78-80 (1997).
9. C. Gates and R. J. Pinney. Amphotericin B and its delivery by liposomal and lipid formulations. J. Clin. Pharm. Ther. 18:147-153 (1993).
10. K. M. Wasan, K. Vadiei, G. Lopez-Berestein, and D. R. Luke. Pharmacokinetics, tissue distribution, and toxicity of free and liposomal amphotericin B in diabetic rats. J. Infect. Dis. 161:562-566 (1990).
11. K. M. Wasan, V. B., Grossie Jr, and G., Lopez-Berestein. Concentrations in serum and tissue distribution of free and liposomal amphotericin B in rats on continuous Intralipid infusion. Antimicrob. Agents Chemother. 38:2224-2226 (1994).
12. K. M. Wasan, M. G. Rosenblum, L. Cheung, and G. Lopez-Berestein. Influence of lipoproteins on renal cytotoxicity and antifungal activity of amphotericin B. Antimicrob. Agents Chemother. 38:223-227 (1994).
13. K. M. Wasan and S. M. Cassidy. The role of plasma lipoproteins in modifying the biological activity of hydrophobic drugs. J. Pharm. Sci. 87:411-424 (1998).
14. K. M. Wasan, A. L. Kennedy, S. M. Cassidy, M. Ramaswamy, L. Holtorf, J. W. L. Chou, and P. H. Pritchard. Pharmacokinetics, Distribution in Serum Lipoprotein and Tissues, and Renal Toxicities of Amphotericin B and Amphotericin B Lipid Complex in a Hypercholesterolemic Rabbit Model: Single-Dose Studies. Antimicrob. Agents Chemother. 42:3146-3152 (1998).
15. B. Baas, K. Kindt, A. Scott, J. Scott, P. Mikulecky, and S. C. Hartsel. Activity and kinetics of dissociation and transfer of amphotericin b from a novel delivery form. AAPS Pharm Sci 1 (1999).
16. F. Gaboriau, M. Cheron, C., Petit, and J. Bolard. Heat-induced superaggregation of amphotericin B reduces its in vitro toxicity: a new way to improve its therapeutic index. Antimicrob. Agents Chemother. 41:2345-2351 (1997).
17. S. C. Hartsel, B. Baas, E. Bauer, L. T. Foree, K. Kindt, H. Preis, A. Scott, E. H. Kwong, M. Ramaswamy, and K. M. Wasan. Heat-induced superaggregation of amphotericin B modifies its interaction with serum proteins and lipoproteins and stimulation of TNF-α. J. Pharm. Sci. 90:124-133 (2001).
18. C. Petit, M. Cheron, V. Joly, J. M. Rodrigues, J. Bolard, and F. Gaboriau. In-vivo therapeutic efficacy in experimental murine mycoses of a new formulation of deoxycholate-amphotericin B obtained by mild heating. J. Antimicrob. Chemother. 42:779-785 (1998).
19. C. Petit, V. Yardley, F. Gaboriau, J. Bolard, and S. L. Croft. Activity of a heat-induced reformulation of amphotericin B deoxycholate (fungizone) against Leishmania donovani. Antimicrob. Agents Chemother. 43:390-392 (1999).
20. P. D. Rogers, K. S. Barker, V. Herring, and M. Jacob. Heat-induced superaggregation of amphotericin B attenuates its ability to induce cytokine and chemokine production in human monocytic cell line THP-1. J. Antimicrob. Agents Chemother. 51:405-408 (2003).
21. E. H. Kwong, M. Ramaswamy, E. A. Bauer, S. C. Hartsel, and K. M. Wasan. Heat treatment of Amphotericin B modifies its serum pharmacokinetics, tissue distribution, and renal toxicity following administration of a single intravenous dose to rabbits. Antimicrob. Agents Chemother. 45:2060-2063 (2001).
22. K. H. Bartlett, E. Yau, S. C. Hartsel, A. Hamer, G. Tsai, D. Bizzotto, and K. M. Wasan. Effect of heat-treated Amphotericin B on renal and fungal cytotoxicity. Antimicrob. Agents Chemother. 48:333-336 (2004).